Yoshinobu Kanda
Jichi Medical University
Internal medicineSurgeryOncologyRetrospective cohort studyHuman leukocyte antigenHematologyImmunologyHazard ratioChemotherapyHematopoietic stem cell transplantationLeukemiaMyeloid leukemiaGraft-versus-host diseaseBone marrowStem cellTransplantationIn patientIncidence (epidemiology)MedicineCumulative incidenceGastroenterology
514Publications
38H-index
11.6kCitations
Publications 513
Newest
#1Akinao Okamoto (Fujita Health University)H-Index: 9
#2Yoshinobu Kanda (Jichi Medical University)H-Index: 38
Last. Kazuo Tamura (Fukuoka University)H-Index: 50
view all 0 authors...
Objectives null Bloodstream infection (BSI) is a frequent complication observed in patients with febrile neutropenia (FN). BSI risk factors and incidence vary depending on chemotherapy types and prophylactic antimicrobial agents. We clarified these issues by post-hoc analysis of a prospective clinical trial cohort for severe FN in hematological malignancy. null Methods null We performed an intention-to-treat analysis of 413 high-risk patients and 1272 blood culture sets. null Results null Overal...
Source
#1Takaaki Konuma (UTokyo: University of Tokyo)H-Index: 22
#2Junya KandaH-Index: 27
Last. Noriko DokiH-Index: 13
view all 0 authors...
PURPOSE The anti-leukemic activity of allogeneic hematopoietic cell transplantation (HCT) depends on both the intensity of conditioning regimen and the strength of the graft-versus-leukemia (GVL) effect. However, it is unclear whether the sensitivity of the GVL effects differs between donor type and graft source. EXPERIMENTAL DESIGN We retrospectively evaluated the effect of acute and chronic graft-versus-host disease (GVHD) on transplant outcomes for adults with acute leukemia (n=6548) between ...
Source
#1Momoko Nakamura (Kyoto University)H-Index: 1
#2Yasuyuki Arai (Kyoto University)H-Index: 14
Last. Masashi SawaH-Index: 13
view all 0 authors...
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) is one of the curative treatment options for acute lymphoblastic leukaemia (ALL). However, the outcomes in patients transplanted without complete remission (non-CR) have not yet been fully reported, and detailed analyses are required to identify subgroups in which optimal prognosis is expected and to optimize pre-transplant therapeutic strategies. Hence, we performed a multicentred retrospective cohort study including a total of 663...
Source
#1Hideki Nakasone (Jichi Medical University)H-Index: 23
#2Shinichi Kako (Jichi Medical University)H-Index: 19
Last. Emiko Sakaida (Chiba University)H-Index: 15
view all 0 authors...
Abstract null Background null : Molecular relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has been thought to predict clinical relapse in patients with Philadelphia chromosome−positive acute lymphoblastic leukemia (PhALL). Tyrosine kinase inhibitor (TKI) administration after allo-HCT may dynamically change the status from molecular relapse to molecular remission, but these state changes cannot be accurately represented by conventional survival indicators such as relapse-fr...
Source
#2Masahiko Hara (Shimane University)H-Index: 2
Last. Yoshinobu Kanda (Jichi Medical University)H-Index: 38
view all 0 authors...
Source
#1Sachiko Seo (Dokkyo Medical University)H-Index: 9
#2Yoshiaki UsuiH-Index: 3
Last. Junya Kanda (Kyoto University)H-Index: 27
view all 20 authors...
Impact of donor age considering HLA disparity on hematopoietic cell transplantation (HCT) outcomes has not been fully evaluated. We evaluated 8486 patients who received unrelated bone marrow transplantation (UR-BMT) from 8/8 or 7/8 HLA-matched donors. Compared to 8/8 HLA-matched younger donors (<40 years), 8/8 HLA-matched older donors (subdistribution hazard ratio [SHR], 1.16; 95% CI, 0.97-1.38) and 7/8 HLA-matched younger donors (SHR, 1.33; 95% CI, 1.11-1.58) were associated with increased risk...
Source
#1Takaaki Konuma (UTokyo: University of Tokyo)H-Index: 22
#2Jun AokiH-Index: 10
Last. Yoshiko Atsuta (Nagoya University)H-Index: 50
view all 15 authors...
Abstract Background : Most patients of myelodysplastic syndrome (MDS) require red blood cell (RBC) and/or platelet transfusion during their disease courses, which could cause an increased risk of iron overload and alloimmunization. However, it remains less clear whether pre-transplant RBC or platelet transfusion burden affects transplant outcomes in patients with MDS. Objective : The objective was to examine the significance of pre-transplant RBC and platelet transfusion burden on transplant out...
Source
#1Shunto Kawamura (Jichi Medical University)H-Index: 2
#2Hideki Nakasone (Jichi Medical University)H-Index: 23
Last. Yoshinobu Kanda (Jichi Medical University)H-Index: 38
view all 17 authors...
Abstract Background Recipient cytomegalovirus (CMV) seropositivity is known to be a risk factor for CMV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HCT). Objective We explored the association of CMV-IgG titer of recipients with CMV reactivation after allo-HCT and aimed to establish a model for predicting CMV reactivation for the purpose of identifying a high-risk group. In addition, we evaluated the impact of CMV-IgG titer on survival outcomes and acute graft-vers...
Source
#1Yoshinobu Kanda (Jichi Medical University)H-Index: 38
#2Masami Inoue (Boston Children's Hospital)H-Index: 29
Last. Yoshihisa Kodera (Aichi Medical University)H-Index: 19
view all 16 authors...
Abstract Background: During the COVID-19 pandemic, donor hematopoietic stem cell grafts are frequently cryopreserved to ensure the availability of graft before starting a conditioning regimen. However, the safety of cryopreservation has been controversial in unrelated hematopoietic stem cell transplantation, especially for bone marrow grafts. In addition, in unrelated HSCT, the effect of the time from harvest to cryopreservation of donor grafts required for the transportation of donor graft has ...
Source
#1Masamitsu YanadaH-Index: 26
#2Takaaki Konuma (UTokyo: University of Tokyo)H-Index: 22
Last. Shingo Yano (Jikei University School of Medicine)H-Index: 18
view all 18 authors...
Posttransplant relapse represents the greatest obstacle to the success of allogeneic hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia (AML). This study investigated clinical features and outcomes of posttransplant relapse of AML based on data for 1265 patients with AML suffering relapse after allogeneic HCT conducted during complete remission (CR). Relapse occurred at a median of 6.1 months. The incidence rate of relapse peaked at 29.0 per 100 patient-years durin...
Source